Peter P. Toth – författare

Lipid management is a key part of medical practice, affecting the prevention and treatment of several diseases, including diabetes, cardiovascular disease and stroke. A practical text on the clinical management of dyslipidemias, Practical Lipid Management balances conceptual development and pathophysiology with a straightforward approach to the identification and treatment of abnormalities in lipid metabolism.

The book explores the role of novel risk markers in clinical practice, summarizes the current guidelines for lipid management, and offers a critical and systematic approach to interpreting the results of clinical trials. A feature of the book is a set of sidebars which explore current controversies and unanswered questions in clinical lipidology. The treatment of specific dyslipidemias is illustrated with case studies. Treatment algorithms are also provided.

Practical Lipid Management:

Practical Lipid Management provides a concise summary of best practice according to various international guidelines, making it a useful tool for all primary care physicians and others involved in the management of diseases such as diabetes, cardiovascular disease and stroke. It will serve as an evidence-based, rapid, and valuable resource for family physicians, internists, nurse practitioners, physician assistants, cardiologists, endocrinologists and allied health professionals involved in the care of patients with lipid disorders.

Diabetes mellitus has become epidemic on a global scale, and millions of new cases are diagnosed every year. The epidemic of diabetes mellitus is expected to result in one of the steepest rises in human morbidity and mortality ever observed outside of wartime. Insulin resistance is a hallmark of pre-diabetes and type 2 diabetes mellitus, and is characterized by impaired insulin-signaling transduction. Authoritative and comprehensive, Lipoproteins in Diabetes Mellitus details the many changes wrought by insulin resistance and diabetes mellitus on lipid and lipoprotein metabolism. The book begins by summarizing the various techniques to measure lipoproteins and their subclasses. The mechanisms by which insulin resistance and diabetes mellitus increase risk for atherosclerosis, diabetic retinopathy, and diabetic nephropathy are then explored in detail. Finally, the effects of lifestyle modification and the results of clinical trials using established and investigational drugs are discussed.

An invaluable contribution to the literature, Lipoproteins in Diabetes Mellitus is a comprehensive reference on the clinical and scientific aspects of lipoproteins in diabetes. It will have a long-lasting and significant effect on the medical management of people with diabetes.

Since the creation of the American Board of Clinical Lipidology, many clinicians have wanted an up-to-date, comprehensive reference on lipidology. Now, for the first time, clinicians can find such a reference in Therapeutic Lipidology. This volume will provide practicing clinicians with a focused and intensive but useable source of information on the identification and management of dyslipidemias. Among the topics discussed in this groundbreaking text are lipoprotein metabolism, pharmacological therapy for cardiovascular disease, thiazolidinediones on serum lipoproteins, hypertriglyceridemia, dyslipidemia and obesity, dyslipidemia in children, and much more.

The pace of scientific and clinical advances in lipidology is astounding. This reference will serve as a lifelong stimulus to the reader to continue to learn about the ever changing and fascinating field of therapeutic lipidology. Comprehensive and cutting-edge, Therapeutic Lipidology will empower readers to improve and extend the lives of the patients they so conscientiously serve.

The second edition of this important book provides an up-to-date and comprehensive overview of clinical lipidology. Brand new chapters focus on recent advances in the field including novel biomarkers and the microbiome, genomics of cardiovascular risks, PCSK9 inhibitors, imaging technologies, and epidemiology of atherosclerotic cardiovascular disease.

The book describes new guidelines, novel therapeutic agents, and changes in the understanding of specific lipoproteins and subclasses with regard to their relationships to cardiovascular disease risk. The second edition contains more than thirty chapters covering such topics as the history of lipidology, lipoprotein metabolism and vascular biology, disorders of lipid metabolism, lifestyle/dietary and pharmacologic management for dyslipidemia, the management of dyslipidemia in certain subgroups (e.g., women, children, older patients) and lipid testing, as well as an examination of other biomarkers and testing procedures related toatherosclerosis and cardiovascular disease. 

The second edition of Therapeutic Lipidology is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.

Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for cardiovascular vascular disease.  Data from case control, epigenetic and mendelian randomization studies indicate that people with elevated Lp(a) have a two-fold to four-fold increased risk of cardiovascular events compared to people with low Lp(a) levels. Despite this risk, awareness of Lp(a) is still very low among health care providers. Even cardiologists often overlook Lp(a), in part because Lp(a) is not as well-understood as other risk factors and treatment options are still very limited. 

Diabetes mellitus has become epidemic on a global scale, and millions of new cases are diagnosed every year. With an estimated 80% of people with diabetes living in disadvantaged regions, and the key roles of lipoproteins in the pathogenesis of the chronic complications of diabetes, this volume will be relevant to many readers globally. It is our intention that the contents will advance knowledge of the readers who will use it to contribute to the reduction of the burden associated with altered lipoproteins in people with diabetes. 

The second edition of this book provides an updated and comprehensive review of the field. The book, which includes many tables and figures, is presented in three main sections: (i) Lipoprotein metabolism, qualitative changes and measurements; (ii) Lipoproteins and the complications of diabetes; and (iii) the treatment of lipoproteins in diabetes. Each chapter from the first edition has been updated, and new topics added. New topicsinclude the links between glycemia and lipoproteins, the role of lipoproteins in ischemic stroke, the diagnosis and management of statin intolerance (which is thought to be more common in people with diabetes) and the use of PCSK9 inhibitors and fish oils in the management of lipoproteins in people with diabetes.  This book is written by an international group of experts in the clinical, laboratory and research aspects of lipoproteins in diabetes.

Lipoproteins in Diabetes Mellitus, 2nd Edition is a comprehensive reference on the clinical and scientific aspects of lipoproteins in diabetes. It is a must-have resource for primary care and specialist clinicians, clinical and basic science researchers and to trainees and students.

This book is a unique, comprehensive board review dedicated solely to preventive cardiology. This volume is a companion work to the ASPC Manual of Preventive Cardiology. The book is comprised of a series of questions, each which addresses a core issue in preventive cardiology. Each question is accompanied with a correct answer key as well as a discussion of why the chosen response is correct, and the others are incorrect. Answers are supported by illustrations and discussion of contemporary literature when applicable. The book also provides references for additional study. This book contains questions written by many of the original authors who contributed to the ASPC Manual of Preventive Cardiology. This book, along with the ASPC Manual of Preventive Cardiology, accompanies the ASPC Experts Course in Preventive Cardiology.

The ASPC Self-Assessment Program in Preventive Cardiology is a valuable resource for cardiologists and other specialists, as well as primary care clinicians (including internists, family physicians, nurse practitioners, and physician assistants) who seek additional training and expertise in cardiovascular disease prevention.